TARGETING LYSYL OXIDASE AS FIRST-IN-CLASS TREATMENT OF CANCER AND FIBROSIS

LoxiPharm

is a new start-up dedicated to the development of therapeutic agents to target LOX, a major driver of both cancer and fibrosis We target high unmet medical needs, rappresenting an attractive global $4.7 bio commercial opportunity

About us

We are a team of enthusiastic, dedicated and motivated young scientists

Janine Erler

Professor in Cancer biology

Prof Janine Erler is a tenured full Professor at the Biotech Research and Innovation Centre (BRIC),
University of Copenhagen, Denmark, where she researches how the tumor microenvironment
drives cancer progression.

Pier Giorgio Amendola

PostDoc

Pier is a postdoctoral scientist at the Erler lab, where he researches novel anti-metastatic therapies, with the intention to move them into clinical trials in human patients.

Funding

Supported by an initial DKK 3.5 mio pre-seed grant from the Novo Nordisk Foundation

Latest News

lorem ipsum

“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi[…]

Read more

lorem ipsum

“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi[…]

Read more

Contact us